Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Evaluation of Efficacy and Safety of MEDI2070 in Patients With Active, Moderate-to-severe Crohn's Disease.

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Allergan
ClinicalTrials.gov Identifier:
NCT01714726
First received: October 24, 2012
Last updated: April 19, 2017
Last verified: April 2017
  Purpose
The study is designed to evaluate the clinical efficacy and safety of MEDI2070 as compared to placebo. Investigational product will be administered as intravenous infusion in double-blind period, and as a subcutaneous injection in open-label period

Condition Intervention Phase
Crohn's Disease
Drug: MEDI2070
Drug: placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Participant, Care Provider, Investigator, Outcomes Assessor
Primary Purpose: Treatment
Official Title: A Phase 2a Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects With Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti-tumor Necrosis Factor-alpha Therapy

Resource links provided by NLM:


Further study details as provided by Allergan:

Primary Outcome Measures:
  • The primary endpoint of the study is Crohn's Disease Activity Index (CDAI) response at Week 8, defined by either a CDAI score of < 150 or a CDAI reduction from baseline of at least 100 points [ Time Frame: Week 8 ]

Secondary Outcome Measures:
  • Crohn's Disease Activity Index (CDAI) remission at Week 8, as defined by a CDAI score of < 150 [ Time Frame: Week 8 ]
  • A reduction of at least 100 points from baseline in Crohn's Disease Activity Index (CDAI) at Week 8 [ Time Frame: Week 8 ]
  • A reduction of at least 70 points from baseline in Crohn's Disease Activity Index (CDAI) at Week 8 [ Time Frame: Week 8 ]
  • Crohn's Disease Activity Index (CDAI) response (either remission defined by CDAI < 150 or a CDAI reduction from baseline of at least 100 points from baseline) at Week 12 [ Time Frame: Week 12 ]
  • Change from baseline Crohn's Disease Activity Index (CDAI) at Week 8 [ Time Frame: Week 8 ]
  • Pharmacokinetic (PK) evaluation of Multiple Doses of MEDI2070 [ Time Frame: Week 0 (Visit 3), Week 4 (Visit 5), Week 8 (Visit 6), Week 24 (Visit 10), Week 112 (Visit 32) predose; Week 0 (Visit 3), Week 4 (Visit 5), postdose ]
  • Immunogenicity (IM) evaluation of Multiple Doses of MEDI2070 [ Time Frame: Week 0 (Visit 3), Week 8 (Visit 6), Week 24 (Visit 10), Week 112(Visit 32) postdose ]

Enrollment: 174
Actual Study Start Date: February 1, 2013
Study Completion Date: December 14, 2016
Primary Completion Date: May 20, 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
MEDI2070 iv infusion
Drug: MEDI2070
1 iv infusion on Week 0 and Week 4
Placebo Comparator: 2
placebo iv infusion
Drug: placebo
1 iv infusion on Week 0 and Week 4
Experimental: open-label
MEDI2070 sc injection; open-label arm is available for all subjects upon completion of first placebo-controlled treatment period
Drug: MEDI2070
1 sc injection of every 4 weeks for 100 weeks, starting at Week 12; open-label arm is available for all subjects upon completion of first placebo-controlled treatment period

Detailed Description:
This is a two-part Phase 2a study compromising a 12-week, double-blind, placebo-controlled, treatment period followed by a 100-week, open label, treatment period to evaluate short-term efficacy, and the short- and long-term safety of MEDI2070 in subjects with moderate to severe, active CD who have failed or are intolerant to anti-TNFα therapy as determined by the investigator. Approximately 120 subjects will be randomized in a 1:1 ratio to initially receive a fixed IV dose of MEDI2070 or placebo on Week 0(Day1) and Week 4 (Day 29) during the 12-week, double-blind, placebo-controlled, treatment period. At the completion of the double-blind, placebo-controlled, treatment period (Week 12), subjects will have the option to enter a 100-week, open-label, treatment period where they will receive open-label MEDI2070 (SC) Q4W (Week 12 through Week 112). Subjects will be followed for safety at 3 visits over 28 weeks after their last dose of IP. Subjects will also be contacted by phone 36 weeks after their last dose of IP for safety.
  Eligibility

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosed ileal, ileo-colonic, or colonic CD at least 6 months prior to screening.
  • Men or women age 18 - 65 years at the time of screening.
  • Moderate-sever active Crohn's Disease (CD), defined by a Crohn's Disease Activity Index (CDAI) score higher or equal 220 and lower or equal 450 at Day 1.
  • No known history of active tuberculosis (TB).
  • Received at least one anti-TNFα agent for the treatment of CD and did not initially respond.

Exclusion Criteria:

  • Pregnant or breastfeeding women.
  • Presence of ileostomy and/or colostomy.
  • Short bowel syndrome.
  • Bowel perforation or obstruction.
  • History of cancer.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01714726

  Show 45 Study Locations
Sponsors and Collaborators
Allergan
Investigators
Study Director: Carl Gommoll, MS Allergan
  More Information

Responsible Party: Allergan
ClinicalTrials.gov Identifier: NCT01714726     History of Changes
Other Study ID Numbers: D5170C00001
2012-004098-26 ( EudraCT Number )
Study First Received: October 24, 2012
Last Updated: April 19, 2017

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Allergan:
MEDI2070
inflammatory bowel disease
moderate to severe Crohn's disease

Additional relevant MeSH terms:
Crohn Disease
Inflammatory Bowel Diseases
Gastroenteritis
Gastrointestinal Diseases
Digestive System Diseases
Intestinal Diseases

ClinicalTrials.gov processed this record on April 21, 2017